Investigators urge caution until more data accrue
Zero cases of structural valve deterioration through latest follow-up
Our experts recap the most notable changes and developments
Database analysis sets stage for a multicenter trial assessing TAVR’s potential role
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
1,000-patient prospective trial to start enrolling patients soon
PARTNER 2 analysis finds few significant effects
PARTNER 3 and CoreValve Low Risk reveal pros and cons of both approaches
Pathophysiologic understanding and deep experience with BAV are invaluable
Review says there’s too much data variance to know
Experts weigh in on proposed changes to reimbursement requirements
Advertisement
Advertisement